Please assess the completion status of the following clinical trial:

Trial Title: Drotaverine in Dysmenorrhoea Treatment

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: DOUBLE
- Phase: PHASE4
- Number of Arms: 3.0

Eligibility Criteria:
Inclusion Criteria:~* History of at least 6 months of dysmenorrhea, with presence of moderate to severe pain in each of the last 3 cycles~* With regular menstrual cycles (25-35 days)~* Using an adequate barrier contraception method (except for virgins)~Exclusion Criteria:~* Evidence of clinically relevant gynecological, cardiovascular, hematologic, hepatic, gastrointestinal, renal, pulmonary, endocrinologic, neurologic or psychiatric disease, based on a clinical assessment and routine laboratory investigations~* Proven hypersensitivity to drotaverine hydrochloride or ibuprofen or proven intolerance to lactose~* Any described contraindication to either drotaverine hydrochloride or ibuprofen (see Summary of Product Characteristics)~* Oestro-progestative contraception within the last 2 months~* Regular use of sedative, hypnotics, tranquillizers or any other addictive agents~* History or evidence of acute or chronic alcohol abuse~* Heavy smoking (\> 10 cigarettes/day)~* Need of a permanent treatment with other antispasmodics and/or analgesic agents during the trial~* Lactation~* Pregnancy~* Participation in another clinical trial in the last 3 months prior to the start of this study~The above information is not intended to contain all considerations relevant to a patient's potential participation in a clinical trial.

- Gender: FEMALE
- Minimum Age: 18 Years
- Maximum Age: 45 Years
- Healthy Volunteers: f

Study Arms:
- drotaverine + Ibuprofen placebo (Type: EXPERIMENTAL): Drotaverine 80 mg plus ibuprofen placebo orally
- Drotaverine placebo + ibuprofen (Type: ACTIVE_COMPARATOR): Drotaverine placebo plus ibuprofen 400 mg orally
- Drotaverine + ibuprofen (Type: ACTIVE_COMPARATOR): Drotaverine 80 mg plus ibuprofen 400 mg orally

Based on this trial design, predict the completion outcome and termination type (if applicable).